The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments, with the Global Generics segment manufacturing and marketing prescription and over-the-counter finished pharmaceutical products and engaging in the biologics business. Revenues grew 11% year over year to $997 million in Q1 fiscal 2026, surpassing consensus estimates, primarily driven by growth in global generics revenues.
Cyborg Score Rationale
Dr. Reddy's Laboratories remains a compelling buy due to underappreciated growth in biosimilars and GLP-1 segments, despite near-term headwinds. The company demonstrates strong revenue growth and strategic positioning in high-growth categories, though it faces pricing pressure in generics and North America headwinds.
Top Insights
Dr. Reddy's signed a collaboration and license agreement with Alvotech to co-develop and commercialize a biosimilar candidate to Merck's blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), across the world.
European operations saw significant growth of 142% YoY, largely driven by the acquired Nicotine Replacement Therapy portfolio.
Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 countries next year.
North America revenues declined 11% YoY due to increased price erosion in products like Lenalidomide.
Named Competitors
Teva Generic Drugs — Global generic pharmaceutical manufacturer
Mylan/Viatris Generics — Major generic and specialty pharma competitor
Aurobindo Pharma — Indian generic and API manufacturer
Cipla — Indian pharmaceutical company with global operations
Recent Developments
(February 2026) Current stock price at $14.31 reflects recent market positioning
(January 2026) FDA accepted Biologic License Application for AVT03 biosimilar to Prolia/Xgeva
(January 2026) Partnership with Bio-Thera for Stelara and Simponi biosimilars in Southeast Asia
(July 2025) Q1 FY26 earnings beat with 11% YoY revenue growth to $997M
Open the full interactive Dr. Reddy's Laboratories Limited report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.